Anti-glomerular basement membrane disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:31 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anti-glomerular basement membrane disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients https://clinicaltrials.eu/trial/study-on-imlifidase-and-drug-combination-for-treating-severe-goodpasture-disease-in-patients/ Wed, 29 Apr 2026 14:24:41 +0000 https://clinicaltrials.eu/trial/study-on-imlifidase-and-drug-combination-for-treating-severe-goodpasture-disease-in-patients/ This clinical trial is focused on studying a rare condition known as Goodpasture disease, which is also referred to as anti-GBM antibody disease. This disease affects the kidneys and lungs, causing them to become inflamed and damaged. The trial aims to compare the effectiveness of a new treatment called imlifidase in combination with standard treatments, against standard treatments alone. The standard treatments include medications such as cyclophosphamide, prednisolone, methylprednisolone, trimethoprim, sulfamethoxazole, and loratadine. These medications are used to suppress the immune system, reduce inflammation, and prevent infections.

The purpose of the study is to determine if the combination of imlifidase and standard treatments can improve kidney function more effectively than standard treatments alone. Participants in the study will receive either the combination treatment or the standard treatment. The study will monitor the participants’ kidney function over a period of time to assess the effectiveness of the treatments. The trial will also look at other factors such as the time it takes for the disease-causing antibodies to reach non-toxic levels and the overall health status of the participants.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to track the progress of their kidney function. The study will last for several months, and participants will undergo regular check-ups and tests to evaluate their response to the treatment. The results of this trial could provide valuable insights into better treatment options for individuals suffering from Goodpasture disease.

]]>